Published on
19:24 GMT
Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models
HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST), demonstrated the ability to significantly reduce tumor burden in humanized mouse models, disrupt KIT signaling pathways and induce tumor cell death, according to a news release …
Source:
Cure Today
-
Neutral
